Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals is well positioned by Rezdiffra’s status as the first approved MASH drug, which gives it a meaningful first-mover advantage in a disease with an estimated 10-20M patients in the US alone and supports the view that early launch metrics can scale into significant revenue. Survey and KOL feedback cited in the excerpts reinforce strong physician preference for Rezdiffra, confidence in its safety profile, and enthusiasm for combination use, while the company’s broader opportunity expands as US peak patients treated are raised to 193k in 2036E and the WW MASH F2/F3 subtyped peak adjusted sales estimate is cited at $7.5B versus $6.3B consensus. The bullish case is further strengthened by Madrigal’s pipeline and platform optionality: potential upside from a 2027E Phase 3 readout in F4, longer-than-street-model exclusivity, and the emergence of ARO-PNPLA3 as a precision asset with up to 46% liver fat reduction at week 12 in I148M homozygotes and no clinically meaningful safety signals, creating a scientifically and commercially compelling combination strategy.

Madrigal Pharmaceuticals is facing a negative fundamental outlook because the core investment case still depends on Rezdiffra’s ability to drive durable commercial traction in MASH while the company’s next growth driver remains highly conditional on regulatory, clinical, and payer execution. Although the Madrigal–Arrowhead deal adds a de-risked, mechanistically orthogonal PNPLA3 program with up to 46% liver fat reduction at week 12 in I148M homozygotes and effect sustained through at least 24 weeks after a single injection, it is still clinical-stage and requires FDA alignment on Phase 2 design, durability, tachyphylaxis, fibrosis benefit, and companion diagnostic strategy before it can materially de-risk the business. Competitive pressure is also intensifying as Wave and ProQR pursue potentially superior RNA-editing approaches, and even if Madrigal maintains a 2–3 year human proof-of-concept lead, that advantage may prove temporary while the company still must prove combination value with Rezdiffra and secure payor coverage for a precision-medicine market that only addresses nearly 30% of F2/F3 MASH patients who are I148M homozygous.